controls with a mean age of 42.12±7.22 mean BMI of 25.87±3.51 with an unsignificant difference between two groups. Serum sclerostin level significantly higher in PsA patients compared to controls with a mean of (0.64 and 0.37ng/ml) respectively, positive significant correlation with patients' age, disease activity scores, ultrasonographic findings of inflammation and damage at the enthesis as well as negative correlation with DEXA at lumbar spine. A positive though non-significant correlation detected between serum sclerostin and Leeds clinical enthesitis index (LEI) and CRP. Conclusions: sclerostin plays important role in pathogenesis of psoriatic arthritis and associated with bone damage either systemic or localized. Further studies for the effect of treatment on serum sclerostin, ultrasonographic and bone mineral density findings is recommended The baseline data from this prospective cohort point to significant differences in the phenotypic expression of PsA between men and women. Thus, in women, the prevalence of dactylitis and pustular psoriasis was higher, there were higher rates of depression and a perception of higher disease activity. Women scored higher on the pain linked to their arthritis and the activity of axial disease. They also had biological activity parameters (ESR) higher than that of men. It is necessary to determine if these differences are maintained or change over time. Background: An association between increased adiposity, obesity (Obs), and psoriasis has emerged. In addition to obesity, patients with psoriasis are more likely to have metabolic syndrome. Objectives: to evaluate the prevalence of endocrine diseases, nutritional and metabolic disorder (ENMD) comorbidity in patients (pts) with PsA and Psoriasis (PsO) patients without arthritis in the dermatological hospital cohort. Methods: 889 pts (Male-516/Female-329) with moderate-to-severy plaque PsO, mean age 50.4±17.6 years, mean PsO duration 21.5±14.7 were included. PsO pts with Endocrine, nutritional and metabolic diseases (E00-E90) (ENMD), including Disorders of thyroid gland (E00-E07), Obesity and other hyperalimentation (E65-E68), Diabetes mellitus (E10-E14) (DM) were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010 -2015 years. M±m, t-test, χ 2 , (%) were calculated. All p<0.05 were considered to indicate statistical significance. Results: 302 out of 889 pts (33.9%) had PsA and 587 out of 889 pts (66.1%) had PsO alone. PsA pts were older then PsO pts -55.3±13.7 and 50.4±17.6 (p<0.001). 155 out of 889 pts (17.4%) had ENMD. In PsA pts ENMD were found in significantly more cases than in PsO pts -in 76 out of 302 pts (25.2%) and in 79 out of 587 pts (13.5%) accordingly (χ 2 =18.986, df=2, p<0.00001). In PsA pts ENMD coding as E00-E07 were found in significantly more cases than in PsO pts -in 25 out of 302 pts (8.3%) and in 23 out of 587 pts (3.9%) accordingly (χ 2 =7.4211, df=2, p=0.00645). Obs coding as E65-E68 were found in significantly more cases in PsA pts compare to PsO pts -in 54 out of 302 pts (17.9%) and in 64 out of 587 pts (10.9%) accordingly (χ 2 =8.4345, df=2, p=0.00368). DM coding as E10-E14 were found in more cases in PsA pts compare to PsO pts -in 54 out of 302 pts (17.9%) and in 83 out of 587 pts (14.1%) accordingly (χ 2 =2.1410, df=2, p=0.14341). Conclusions: ENMD comorbidities are common for PsA and PsO without arthritis pts. Obs and disorders of thyroid gland were found in significantly more cases in PsA pts compare to PsO pts. Obesity and PsA are an unhealthy combination. Obesity may represent an additive cardio-metabolic risk factor in PsA subjects. High frequency of ENMD in PsA than PsO could be due to share inflammation pathways with insulin resistance and age. Patients with more severe psoriasis are at higher odds of endocrine, nutritional and metabolic diseases compared with those with mild psoriasis. Taiwan , and assess physicians' adopted methods and difficulties of diagnosis, therapeutic consideration and strategy, in addition to rationales for biologic agents and unmet needs. Methods: A nationwide cross-sectional observational study in Taiwan was conducted by means of the face-to-face in depth interviews with the 80 physicians, composed of 50 rheumatologists and 30 dermatologists, from November 2014 to January 2015. Results: The major adopted diagnostic examinations for PsA are arthritis performance, psoriasis and nail dystrophy, roentgenological studies, personal and family history; however, more dermatologists rely on RF for initial diagnosis (p<0.05). The difficulties for diagnosis, considerations on therapeutic management and current prescription were reported and displayed some interdisciplinary difference. Rationales for biological agent selection were investigated and physicians generally favored etanercept in terms of milder symptoms or more conservative treatment. The main unmet needs for current biologic therapies for PsA included the aspects of better efficacy, safety, sustainability and oral administration.
Conclusions:
The nationwide study is the first survey for real-world clinical practice of PsA in Asia and provides detailed messages about the diagnostic difficulties and therapeutic consideration, especially rationales and unmet needs on current biologic therapies, which may offer possible directions for new drug development. We also made interdisciplinary comparison, hence in order to improve comprehensive care. 
